Masahiro Takada

Osaka, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 51 publications

Early-Onset Direct Antiglobulin Test-Negative Autoimmune Hemolytic Anemia Induced by Pembrolizumab in Perioperative Triple-Negative Breast Cancer: A Case Report.

Early-Onset Direct Antiglobulin Test-Negative Autoimmune Hemolytic Anemia Induced by Pembrolizumab in Perioperative Triple-Negative Breast Cancer: A Case Report.

Journal: Case reports in oncology

Published: March 13, 2026

Efficacy of olanzapine for prophylaxis of delayed chemotherapy-induced nausea and vomiting in patients with breast cancer receiving dose-dense AC with a steroid-sparing regimen: a single-center pilot study.

Efficacy of olanzapine for prophylaxis of delayed chemotherapy-induced nausea and vomiting in patients with breast cancer receiving dose-dense AC with a steroid-sparing regimen: a single-center pilot study.

Journal: BMC cancer

Published: January 16, 2026

Real-world treatment patterns and outcomes in older patients with metastatic breast cancer: a multi-institutional retrospective cohort study.

Real-world treatment patterns and outcomes in older patients with metastatic breast cancer: a multi-institutional retrospective cohort study.

Journal: Breast cancer research and treatment

Published: January 15, 2026

A case of ER-positive, HER2-negative metastatic breast cancer with high tumor mutation burden achieving complete response to pembrolizumab monotherapy.

A case of ER-positive, HER2-negative metastatic breast cancer with high tumor mutation burden achieving complete response to pembrolizumab monotherapy.

Journal: International cancer conference journal

Published: November 18, 2025

Correction: Real‑world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first‑ or second‑line treatment for hormone receptor-positive, HER2‑negative advanced or metastatic breast cancer.

Correction: Real‑world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first‑ or second‑line treatment for hormone receptor-positive, HER2‑negative advanced or metastatic breast cancer.

Journal: Breast cancer (Tokyo, Japan)

Published: June 23, 2025

Real-world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first- or second-line treatment for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.

Real-world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first- or second-line treatment for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.

Journal: Breast cancer (Tokyo, Japan)

Published: January 28, 2025

Detection capability of the Medical Imaging Projection System for sentinel lymph node biopsy in patients with breast cancer with and without neoadjuvant chemotherapy: a retrospective study.

Detection capability of the Medical Imaging Projection System for sentinel lymph node biopsy in patients with breast cancer with and without neoadjuvant chemotherapy: a retrospective study.

Journal: Breast cancer (Tokyo, Japan)

Published: December 27, 2024

Neoadjuvant palbociclib in women with operable, hormone receptor-positive breast cancer.

Neoadjuvant palbociclib in women with operable, hormone receptor-positive breast cancer.

Journal: Endocrine-related cancer

Published: December 26, 2024

Deep Learning Applied to Diffusion-weighted Imaging for Differentiating Malignant from Benign Breast Tumors without Lesion Segmentation.

Deep Learning Applied to Diffusion-weighted Imaging for Differentiating Malignant from Benign Breast Tumors without Lesion Segmentation.

Journal: Radiology. Artificial intelligence

Published: November 20, 2024

Adjuvant S-1 plus endocrine therapy for ER-positive, HER2-negative, primary breast cancer: post-POTENT trial prognostic survey.

Adjuvant S-1 plus endocrine therapy for ER-positive, HER2-negative, primary breast cancer: post-POTENT trial prognostic survey.

Journal: NPJ breast cancer

Published: September 09, 2024

Automated System to Capture Patient Symptoms From Multitype Japanese Clinical Texts: Retrospective Study.

Automated System to Capture Patient Symptoms From Multitype Japanese Clinical Texts: Retrospective Study.

Journal: JMIR medical informatics

Published: March 29, 2024

Real-World Patient Characteristics, Treatment Patterns, and Outcomes of HR+, HER2- Early Breast Cancer Patients in Japan: An Analysis with National Database(NDB).

Real-World Patient Characteristics, Treatment Patterns, and Outcomes of HR+, HER2- Early Breast Cancer Patients in Japan: An Analysis with National Database(NDB).

Journal: Gan to kagaku ryoho. Cancer & chemotherapy

Published: January 22, 2024

Showing 1-12 of 51

Last Updated: 09/26/2026